Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shenzhen's BGI Has Revamped Plans for $600 Million China IPO

publication date: Apr 13, 2016
BGI, the Shenzhen genomic sequencing powerhouse, is once again proposing an IPO: this time the company intends to list two of its units, BGI Dx and BGI Tech, on the Shenzhen ChiNext exchange. A preliminary prospectus, filed in December 2015, placed a $3 billion valuation on the two subsidiaries, which have been merged. The IPO is expected to offer a 20% stake of the merged entity -- $600 million. BGI Tech provides contract sequencing to life science companies. BGI Dx offers clinical screening tests, especially non-invasive prenatal tests in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China